Biohaven Ltd. (NYSE: BHVN) releases January 2026 investor presentation

Rhea-AI Filing Summary

Biohaven Ltd. disclosed that it will be making an investor presentation on January 12, 2026. The company has prepared an investor slide deck, described as an Investor Presentation dated January 2026, and made it available as an exhibit to this report so that the broader market has access to the same information shared with investors.

The presentation materials are furnished for informational purposes only under Regulation FD, meaning they are not treated as formally filed financial statements or incorporated into other securities law documents unless specifically referenced in the future.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001935979false00019359792026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Biohaven Ltd.

(Exact name of registrant as specified in its charter)

British Virgin Islands			001-41477			Not applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

(203) 404-0410

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Common Shares, no par value			BHVN			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01 Regulation FD Disclosure

On January 12, 2026, Biohaven Ltd. will be making an investor presentation (the “Presentation”). A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Exhibit Description
99.1						Investor Presentation, dated January 2026.
104						The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026

Biohaven Ltd.
By:			/s/ Matthew Buten
			Matthew Buten
			Chief Financial Officer

3

FAQ

What did Biohaven Ltd. (BHVN) disclose in this January 2026 report?

Biohaven Ltd. disclosed that it will be making an investor presentation on January 12, 2026 and has provided the related Investor Presentation dated January 2026 as an exhibit.

What is included in Biohaven Ltd.’s investor materials attached to this report?

The report includes Exhibit 99.1, which is an Investor Presentation dated January 2026, and Exhibit 104, which is the cover page formatted as Inline XBRL.

How is Biohaven Ltd.’s investor presentation treated under U.S. securities laws?

The investor presentation and related information are being furnished under Regulation FD and are not deemed filed or incorporated by reference into other securities law documents unless specifically stated.

Which exchange lists Biohaven Ltd. (BHVN) common shares?

Biohaven Ltd.’s Common Shares, no par value, trade under the symbol BHVN on the New York Stock Exchange.

Who signed this Biohaven Ltd. report on behalf of the company?

The report was signed on behalf of Biohaven Ltd. by Matthew Buten, who is the company’s Chief Financial Officer.